KA/EN
Register
Medicines reference
Search
Search
Active substance

Enrofloxacin

Favourites

Fluoroquinolone. Registered in Georgia: 1 veterinary product. Forms: scored tablet, solution.

Dose and use

Doses

Each dose comes with its source. Check the label of the product you use.

Active substance Enrofloxacin
Dose calculatorCalculates the active-substance amount; it is not a prescription.
PatientSpecies and weight will be filled in automatically in other calculators.
Selected dose
Dose Species Indication Route Frequency Source
5 mg/kg Dog, Cat Bacterial Infection; Urinary Tract Infection; Skin and Soft Tissue Infection By mouth / Subcutaneous once daily
VMD SPC 2025
Official product label (SPC), VMD, UK
Approved by the UK Veterinary Medicines Directorate (VMD) as part of the product's authorisation. It applies to that product as authorised there.
Baytril Flavour Tablets 15 mg - Summary of Product Characteristics
UK Veterinary Medicines Directorate, Product Information Database, 2025
VMD SPC 2025
Official product label (SPC), VMD, UK
Approved by the UK Veterinary Medicines Directorate (VMD) as part of the product's authorisation. It applies to that product as authorised there.
Xeden 150 mg tablet for dogs - Summary of Product Characteristics
UK Veterinary Medicines Directorate, Product Information Database, 2025
VMD SPC 2026
Official product label (SPC), VMD, UK
Approved by the UK Veterinary Medicines Directorate (VMD) as part of the product's authorisation. It applies to that product as authorised there.
Baytril 25 mg/ml Solution for Injection - Summary of Product Characteristics
UK Veterinary Medicines Directorate, Product Information Database, 2026
VMD SPC 2026
Official product label (SPC), VMD, UK
Approved by the UK Veterinary Medicines Directorate (VMD) as part of the product's authorisation. It applies to that product as authorised there.
Enrocat Flavour 25 mg/ml Oral Suspension for Cats - Summary of Product Characteristics
UK Veterinary Medicines Directorate, Product Information Database, 2026
FDA 2026
Official product label (SPC), FDA, US
Approved by the US Food and Drug Administration (FDA) as part of the product's authorisation. It applies to that product as authorised there.
Baytril (enrofloxacin) Taste Tabs - FDA-approved animal drug label, NADA 140-441
US Food and Drug Administration, via DailyMed, 2026
5–20 mg/kg Dog Bacterial Infection By mouth once daily
FDA 2026
Official product label (SPC), FDA, US
Approved by the US Food and Drug Administration (FDA) as part of the product's authorisation. It applies to that product as authorised there.
Baytril (enrofloxacin) Taste Tabs - FDA-approved animal drug label, NADA 140-441
US Food and Drug Administration, via DailyMed, 2026
10–20 mg/kg Dog Skin and Soft Tissue Infection By mouth once daily
ISCAID 2025
Guideline or consensus statement
Recommendations agreed by a panel of veterinary specialists after reviewing the evidence. They guide practice and do not authorise a product.
Antimicrobial use guidelines for canine pyoderma by the International Society for Companion Animal Infectious Diseases (ISCAID)
Veterinary Dermatology, 2025
Before use

Safety information

Known Contraindications

  • Critical
    Do not use enrofloxacin in animals with epilepsy, seizures, or seizure disorders associated with the central nervous system, because it may stimulate the CNS.
    Sources: VMD SPC · VMD · FDA
  • Critical
    Do not use in animals hypersensitive to the active substance, another fluoroquinolone, or any excipient. Do not use against known quinolone resistance because cross-resistance is extensive. Treat Pseudomonas infections only after susceptibility testing.
    Sources: VMD SPC · VMD
  • Critical (Dog)
    Not for use in dogs less than 1 year of age or in exceptionally large breeds of dog with a longer growth period under 18 months of age. has not been established
    Sources: VMD · FDA
  • Critical (Cat)
    In rare instances, use of this product in cats has been associated with Retinal Toxicity. Do not exceed 5 mg/kg of body weight per day in cats. from 20 mg/kg Mydriasis, retinal degeneration... loss of vision. Mydriasis may be an indication of impending or existing retinal changes.
    Sources: FDA
  • Critical (Cat)
    Minimum age differs by product. Some labels prohibit use in kittens younger than 8 weeks; others prohibit use below 3 months of age or below 1 kg because of cartilage injury risk. Use the limit stated for the specific product; the most conservative limit is 3 months and 1 kg.
    Sources: FDA
  • Warning
    Elimination may be delayed in animals with pre-existing renal damage. Use with caution in severe renal or hepatic impairment.
    Sources: VMD SPC · VMD
  • Warning
    Use with caution in severe hepatic impairment. Concomitant administration with other hepatically metabolized medicines may reduce clearance of both the quinolone and the other medicine.
    Sources: VMD SPC · VMD · FDA
  • Warning
    The use is not recommended during pregnancy The safety of the veterinary medicinal product has not been established during pregnancy and lactation Safety in breeding or pregnant cats has not been established The veterinary medicinal product may be used safely in pregnant and lactating animals
    Sources: VMD · FDA
  • Warning
    the use is not recommended during lactation may be used safely in pregnant and lactating animals
    Sources: VMD

Known Drug Interactions

  • Major warning Enrofloxacin + Aminophylline
    Theophylline metabolism is inhibited by erythromycin, cimetidine, propranolol, enrofloxacin, and marbofloxacin
    Recommendation: Reduce the aminophylline dose during concomitant use. Signs of toxicity include vomiting, excitation, tachyarrhythmia, and seizures.
    Sources: MSD Vet Manual
  • Major warning Enrofloxacin + Doxycycline
    Do not combine enrofloxacin with antimicrobials that act antagonistically to quinolones, including macrolides, tetracyclines such as doxycycline, and phenicols such as chloramphenicol.
    Recommendation: Do not administer concurrently. Based on susceptibility testing, choose either a bactericidal fluoroquinolone or a bacteriostatic tetracycline.
    Sources: VMD SPC · VMD
  • Major warning Enrofloxacin + Theophylline
    Do not use concurrently with theophylline as the elimination of theophylline may be delayed Concomitant administration of theophylline requires careful monitoring as serum levels of theophylline may increase
    Recommendation: Avoid the combination where possible. If concomitant use is unavoidable, monitor serum theophylline and be prepared to reduce its dose.
    Sources: VMD
  • Minor warning Enrofloxacin + Sucralfate
    The concomitant administration of substances containing magnesium or aluminium may reduce the absorption of enrofloxacin. These drugs should be administered two hours apart.
    Recommendation: Separation is not critical in dogs, but a 2-hour interval is safe and label-consistent. No comparable measurement exists in cats; use a 2-hour interval in cats.
    Sources: VMD SPC · VMD · JVIM
Latin name
Enrofloxacin
Georgian name
ენროფლოქსაცინი
Authorisation status
Authorised veterinary medicine
An authorised veterinary medicine containing this substance exists. Whether a particular use is on-label depends on the species and the indication - see each dose rule.
Registered in Georgia
1 of 2 forms
Products
Enrocure, Enroxil Flavour
Controlled in Georgia
No
Checked against the narcotics law, Annex 1, lists I-IV, and Order No. 22/n.
Verified on: 16 Oct 2026
All forms and registration2

Registration in Georgia and abroad: the register, number, validity and source are behind (i).

Enrocure 10%, Solution

100 mg/ml, solution for injection
vetman assessment
vetman’s 10-point assessment brings together a product’s regulatory credibility, clinical efficacy, safety and practicality. Cost-effectiveness is assessed only when reliable data are available. It is informational and does not replace a veterinarian’s clinical judgment for an individual patient.
Dog Proposed parenteral treatment of a culture-confirmed enrofloxacin-susceptible bacterial infection in a dog using exact Teknovet Enrocure 10%
Not rateable
No numerical score assigned
vetman assessment

Enrocure

10%, 100 mg/ml, solution for injection
Assessed clinical scopeDog · Proposed parenteral treatment of a culture-confirmed enrofloxacin-susceptible bacterial infection in a dog using exact Teknovet Enrocure 10% · IV,SC
Care settingNo established companion-animal treatment pathway; select an authorised exact dog/cat presentation after diagnosis, culture and susceptibility review
vetman score Not rateable No numerical score assigned
Evidence confidence: Medium Georgia: Expired · № 002523, 002550, 002551 · Verified on 22 Oct 2026 Off-label use
Not rateable

A numerical score cannot responsibly be assigned for dogs. Exact Teknovet Enrocure 10% is transparently identified, but its current label covers cattle, sheep and goats only and its Georgian authorisations expired on 2026-10-06. The ready solution contains 100 mg/ml enrofloxacin plus 30 mg/ml n-butanol. Current authorised companion-animal comparators are different products: GB Baytril is 25 mg/ml for dogs/cats, while US Baytril injection is 22.7 mg/ml, dog-only and used as a single IM loading dose. No Enrocure dog/cat dose, PK or bioequivalence bridge, validated dilution, dose-delivery study, local-tolerance/target-animal safety study or clinical outcome evidence was located. Ingredient efficacy and a matching nominal mg/kg number cannot establish this exact presentation’s benefit-risk.

Enrofloxacin has established veterinary antibacterial roles and authorised dog/cat formulations. That supports choosing an exact companion-animal product; it does not validate this expired-market, food-animal 100 mg/ml presentation. Publish no dog/cat dose or numerical product score.

Important safety and use flags

  • Exact-product boundary: current Teknovet Enrocure 10% is a 100 mg/ml cattle/sheep/goat product. Dogs and cats are absent from its target species, indications and regimen.
  • The historical Georgian authorisations expired on 2026-10-06 and the exact product is absent from the current NFA register. Retail availability does not restore authorisation or supply companion-animal evidence.
  • Do not transfer Baytril 25 mg/ml dosing. It is a different, four-fold less concentrated authorised dog/cat product; the shared 30 mg/ml n-butanol preservative and active ingredient do not establish bioequivalence or local tolerance.
  • Do not transfer US Baytril injection dosing. That 22.7 mg/ml dog-only product is used as one IM loading dose followed by tablets; it neither supports cats nor repeated Enrocure IV/SC treatment.
  • No calculator dose is published. A hypothetical 5 mg/kg conversion would be 0.1 ml in a 2 kg cat and 0.2 ml in a 4 kg cat; these figures illustrate dose-delivery risk but do not validate a regimen, syringe choice or improvised dilution.
  • Fluoroquinolones are EMA AMEG Category B (Restrict). Use only when culture/susceptibility and infection-site evidence justify them and a lower-category appropriate antimicrobial is unsuitable.
  • Avoid in growing dogs before skeletal maturity because fluoroquinolones can damage weight-bearing articular cartilage. Exact Enrocure canine age limits and target-animal safety are unknown.
  • Do not use against quinolone-resistant organisms. Cross-resistance is extensive; treatment failure requires diagnosis, source-control and susceptibility review, not blind dose escalation.
  • Exact-product dog/cat pregnancy, lactation, organ-disease, injection-site tolerance and repeated-dose safety are not established. Do not infer them from food-animal use or another enrofloxacin formulation.
  • Review interactions before any enrofloxacin use: avoid antagonistic tetracyclines/macrolides/phenicols; theophylline exposure can rise. Do not mix or dilute Enrocure without product-specific compatibility and stability evidence.
Assessment sources
  1. Teknovet Enrocure 10%2026
  2. Enrocure expired GE record2026
  3. Enrocure current GE audit2026
  4. Baytril 25 VMD label2025
  5. FDA Baytril dog injection1990
  6. FDA feline retinal cap2001
  7. EMA AMEG 20252025
  8. ISCAID canine pyoderma 20252025
Assessed: 22 Oct 2026No axis or overall score is shown when the available evidence does not support a responsible numerical assessment.
Cat Proposed parenteral treatment of a culture-confirmed enrofloxacin-susceptible bacterial infection in a cat using exact Teknovet Enrocure 10%
Not rateable
No numerical score assigned
vetman assessment

Enrocure

10%, 100 mg/ml, solution for injection
Assessed clinical scopeCat · Proposed parenteral treatment of a culture-confirmed enrofloxacin-susceptible bacterial infection in a cat using exact Teknovet Enrocure 10% · IV,SC
Care settingNo established companion-animal treatment pathway; select an authorised exact dog/cat presentation after diagnosis, culture and susceptibility review
vetman score Not rateable No numerical score assigned
Evidence confidence: Medium Georgia: Expired · № 002523, 002550, 002551 · Verified on 22 Oct 2026 Off-label use
Not rateable

A numerical score cannot responsibly be assigned for cats. Exact Teknovet Enrocure 10% is transparently identified, but its current label covers cattle, sheep and goats only and its Georgian authorisations expired on 2026-10-06. The ready solution contains 100 mg/ml enrofloxacin plus 30 mg/ml n-butanol. Current authorised companion-animal comparators are different products: GB Baytril is 25 mg/ml for dogs/cats, while US Baytril injection is 22.7 mg/ml, dog-only and used as a single IM loading dose. No Enrocure dog/cat dose, PK or bioequivalence bridge, validated dilution, dose-delivery study, local-tolerance/target-animal safety study or clinical outcome evidence was located. Ingredient efficacy and a matching nominal mg/kg number cannot establish this exact presentation’s benefit-risk.

Enrofloxacin has established veterinary antibacterial roles and authorised dog/cat formulations. That supports choosing an exact companion-animal product; it does not validate this expired-market, food-animal 100 mg/ml presentation. Publish no dog/cat dose or numerical product score.

Important safety and use flags

  • Exact-product boundary: current Teknovet Enrocure 10% is a 100 mg/ml cattle/sheep/goat product. Dogs and cats are absent from its target species, indications and regimen.
  • The historical Georgian authorisations expired on 2026-10-06 and the exact product is absent from the current NFA register. Retail availability does not restore authorisation or supply companion-animal evidence.
  • Do not transfer Baytril 25 mg/ml dosing. It is a different, four-fold less concentrated authorised dog/cat product; the shared 30 mg/ml n-butanol preservative and active ingredient do not establish bioequivalence or local tolerance.
  • Do not transfer US Baytril injection dosing. That 22.7 mg/ml dog-only product is used as one IM loading dose followed by tablets; it neither supports cats nor repeated Enrocure IV/SC treatment.
  • No calculator dose is published. A hypothetical 5 mg/kg conversion would be 0.1 ml in a 2 kg cat and 0.2 ml in a 4 kg cat; these figures illustrate dose-delivery risk but do not validate a regimen, syringe choice or improvised dilution.
  • Fluoroquinolones are EMA AMEG Category B (Restrict). Use only when culture/susceptibility and infection-site evidence justify them and a lower-category appropriate antimicrobial is unsuitable.
  • Cats have a label- and post-market-supported risk of irreversible retinal degeneration and blindness when the enrofloxacin exposure ceiling is exceeded. Exact Enrocure feline ocular safety and overdose margin are unknown.
  • Do not use against quinolone-resistant organisms. Cross-resistance is extensive; treatment failure requires diagnosis, source-control and susceptibility review, not blind dose escalation.
  • Exact-product dog/cat pregnancy, lactation, organ-disease, injection-site tolerance and repeated-dose safety are not established. Do not infer them from food-animal use or another enrofloxacin formulation.
  • Review interactions before any enrofloxacin use: avoid antagonistic tetracyclines/macrolides/phenicols; theophylline exposure can rise. Do not mix or dilute Enrocure without product-specific compatibility and stability evidence.
Assessment sources
  1. Teknovet Enrocure 10%2026
  2. Enrocure expired GE record2026
  3. Enrocure current GE audit2026
  4. Baytril 25 VMD label2025
  5. FDA Baytril dog injection1990
  6. FDA feline retinal cap2001
  7. EMA AMEG 20252025
  8. ISCAID canine pyoderma 20252025
Assessed: 22 Oct 2026No axis or overall score is shown when the available evidence does not support a responsible numerical assessment.
Composition / strength
Enrofloxacin100 mg/ml
Formulation Type
Solution
Administration route
Intravenous, Subcutaneous
Registration
Georgia Expired
Expired on 06 Oct 2026, not renewed yet
Veterinary (National Food Agency)
In the register: ენროკური® 10%
№ 002523, 002550, 002551
Verified on: 22 Oct 2026
 EU No
Verified on: 22 Oct 2026
 UK No
Verified on: 22 Oct 2026
 US No
Verified on: 22 Oct 2026
Controlled in Georgia
No
Checked against the narcotics law, Annex 1, lists I-IV, and Order No. 22/n.
Verified on: 16 Oct 2026
Information not fully verified No dog or cat dose or route is established for exact Teknovet Enrocure 10%. Its current official label covers cattle, sheep and goats only. Do not transfer the Baytril 25 mg/ml dog/cat 5 mg/kg SC regimen, the US 22.7 mg/ml dog IM loading regimen, or the food-animal 5 mg/kg regimen to this 100 mg/ml presentation. Use an authorised exact companion-animal product.

Enroxil Flavour 50 mg, Scored tablet

enrofloxacin 50 mg, scored tablet for dogs
vetman assessment
vetman’s 10-point assessment brings together a product’s regulatory credibility, clinical efficacy, safety and practicality. Cost-effectiveness is assessed only when reliable data are available. It is informational and does not replace a veterinarian’s clinical judgment for an individual patient.
Dog
7.6/10
Good
vetman assessment

Enroxil Flavour

50 mg, enrofloxacin 50 mg, scored tablet for dogs
Assessed clinical scopeDog · Complete dog label: oral treatment of susceptible bacterial alimentary, respiratory, urogenital, skin, secondary-wound and otitis externa infections when enrofloxacin is the justified drug of choice · By mouth
Care settingOutpatient reserve-antimicrobial treatment after diagnosis and accurate weighing, with susceptibility testing whenever possible and planned clinical reassessment
vetman score 7.6/10 Good
Evidence confidence: Medium Georgia: Yes, veterinary · № 162-11; 15-11 · Verified on 22 Oct 2026

A well-documented, practical oral enrofloxacin presentation for an accurately diagnosed susceptible infection in an adult dog. Its value is good—not routine—because fluoroquinolones are Category B Restrict and should follow susceptibility-led justification when lower-category effective options are unsuitable.

Regulatory and scientific credibility9.0/10

The exact 50 mg presentation has current transparent EU and Georgian authorisations plus a current aligned KRKA GB authorisation/SPC. FDA-approved oral enrofloxacin products independently support the active/form endpoint, although this exact KRKA presentation is not FDA approved.

Clinical efficacy7.0/10

Enrofloxacin has established concentration-dependent activity and an exact authorised 5 mg/kg regimen across the susceptible dog label. Benefit remains organism-, site- and susceptibility-dependent; resistance and modern syndrome guidance make it a reserve rather than broad empirical default, and independent exact-generic outcome data across every bundled indication are limited.

Safety and tolerability6.5/10

Correctly selected adult dogs usually have a workable margin and very rare anorexia/vomiting, but rapid-growth cartilage injury, seizure/CNS risk, renal/hepatic caution, milk transfer, overdose without an antidote and clinically important antimicrobial, theophylline, anticoagulant and chelation interactions are material.

Clinical practicality8.0/10

Once-daily dosing, food flexibility, a 5-10-day course and half-tablet division are practical for correctly sized dogs. The 50 mg tablet supplies validated 5 kg steps only; smaller or intermediate doses need a more suitable strength rather than quarters/crushing, and a used half expires after 24 hours.

Full-course cost-effectiveness-

Current Georgian full-course price was unavailable; price is excluded from the denominator.

Important safety and use flags

  • Scope boundary: this is one assessment of the complete authorised susceptible-infection dog scope. It does not endorse prophylaxis, undiagnosed non-bacterial disease, every listed organism without susceptibility, cats or another enrofloxacin strength/formulation.
  • Stewardship hard stop: fluoroquinolones are EMA AMEG Category B (Restrict). Prefer an effective Category D/C or narrower option; use culture/susceptibility whenever possible and document why enrofloxacin is the justified choice.
  • Do not use in dogs under one year or exceptionally large breeds under 18 months: articular cartilage can be affected during rapid growth. Joint-cartilage disorder has an undetermined frequency.
  • Do not use in dogs with seizure disorders because CNS stimulation can occur. Stop and reassess neurologic or behavioural change; overdose can cause GI and CNS signs and has no specific antidote.
  • Use caution in severe renal or hepatic impairment and do not exceed 5 mg/kg/day. Weigh accurately and reassess exposure, response and organ function where clinically indicated.
  • Very rare anorexia and vomiting are reported. Reassess persistent GI signs, treatment failure, superinfection or clinical deterioration; source control and diagnosis matter more than blind dose escalation.
  • Do not combine with tetracyclines, phenicols or macrolides because of potential antagonism. Review oral anticoagulants and theophylline; separate or otherwise manage magnesium/aluminium products because absorption may be delayed.
  • Exact dose: 5 mg/kg/day PO for 5-10 days, once daily or the daily amount divided twice, with or without food. The 50 mg tablet equals 10 kg and validates halves only; do not invent quarters, crush-derived doses or the US 5-20 mg/kg range.
  • Enrofloxacin passes into milk; use during lactation only after veterinary benefit-risk assessment. The current exact SPC provides no separate pregnancy assurance, so do not infer pregnancy safety.
  • Return a half-tablet to the opened blister and use within 24 hours. Wash hands, avoid contact after known quinolone hypersensitivity and seek medical advice after accidental ingestion.
Assessment sources
  1. EU SPC 20252025
  2. Enrox 50 VMD SPC2025
  3. Enroxil GE register2026
  4. EMA AMEG 20252025
  5. FDA 20262026
  6. ISCAID 20252025
  7. ISCAID urinary 20192019
  8. ISCAID 20172017
Assessed: 22 Oct 2026The overall score uses 25/25/25/15/10 weights. An unassessed price is excluded and the remaining weights are proportionally renormalised.
Composition / strength
Enrofloxacin50 mg
Formulation Type
Scored tablet
Administration route
By mouth
Manufacturer
KRKA-Farma d.o.o. · Croatia
Registration
Georgia Yes, veterinary
Veterinary (National Food Agency)
In the register: ენროქსილ ფლეივორი 50 მგ
№ 162-11; 15-11
Verified on: 22 Oct 2026
 EU Yes, veterinary
№ UP/I-322-05/20-01/513
Verified on: 22 Oct 2026
 UK Yes, veterinary
№ Vm 01656/4008
Verified on: 22 Oct 2026
 US No
Verified on: 22 Oct 2026
Controlled in Georgia
No
Checked against the narcotics law, Annex 1, lists I-IV, and Order No. 22/n.
Verified on: 16 Oct 2026
Information not fully verified Prescription-only reserve fluoroquinolone. For diagnosed susceptible infections within the authorised dog scope when enrofloxacin is the justified choice, preferably supported by culture/susceptibility. Give 5 mg/kg/day PO for 5-10 days, once daily or as the daily amount divided twice, with or without food. One 50 mg tablet/10 kg; halves only. Weigh accurately, reassess before extending and use a returned blistered half within 24 hours.

Professional reference for veterinary professionals. Not advertising and not a substitute for the product label/SPC.

For veterinary professionals only. It does not replace clinical judgement or the product label; check the dose in the official label (SPC). vetman is not liable for harm caused by using this information.

Trademarks belong to their owners; vetman is not affiliated with the manufacturers and receives no payment from them.

The database is protected under Chapter VII of the Law of Georgia on Copyright and Related Rights; automated or bulk copying is prohibited.

This reference is still growing. Missing a product? Let us know. · Report an error or request an addition · Updated: 23 Oct 2026

All of this shows in vetman as you prescribe

The dose for the patient's weight, registration in Georgia and controlled status, right on the prescription.

Register Demo ↗